Thank you for rejoining the board and setting the record straight. That is Due Diligence at its finest and shows the value of open discussion.
We can't predict the future but so far there have been very few days one could have bought CTIX and not already been in profit. There is always risk, but there is also great potential here.
Cellceutix is a very unique company.
I can't find a single other example of a biotech company so well positioned in terms of share structure and financing going into clinical trials. Most require heavy dilution, yet the fantastic terms of the Aspire Capital financing, the owners deferring salary and providing financing, and the wonderful, cost saving arrangements with leading cancer research hospitals give CTIX shareholders great protection.
These world renown research hospitals and universities don't act recklessly with their resources, there is something about Kevetrin that has really focused their attention.